{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T04:09:19Z","timestamp":1794888559436,"version":"4.9.1"},"reference-count":68,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T00:00:00Z","timestamp":1737331200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.eururo.2025.01.010","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T17:22:32Z","timestamp":1739380952000},"page":"455-467","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["Combination Therapies in Locally Advanced and Metastatic Hormone-sensitive Prostate Cancer"],"prefix":"10.1016","volume":"87","author":[{"given":"Arun A.","family":"Azad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Kostos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhardt","family":"Attard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian D.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Dorff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Gillessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Sweeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Tombal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Fizazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2025.01.010_b0005","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","article-title":"The Lancet Commission on prostate cancer: planning for the surge in cases","volume":"403","author":"James","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2025.01.010_b0010","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1001\/archsurg.1941.01210140043004","article-title":"Studies on prostatic cancer: II. The effects of castration on advanced carcinoma of the prostate gland","volume":"43","author":"Huggins","year":"1941","journal-title":"Arch Surg"},{"key":"10.1016\/j.eururo.2025.01.010_b0015","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.eururo.2018.02.001","article-title":"Burden of metastatic castrate naive prostate cancer patients, to identify men more likely to benefit from early docetaxel: further analyses of CHAARTED and GETUG-AFU15 studies","volume":"73","author":"Gravis","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.01.010_b0020","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/pros.23645","article-title":"Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC)","volume":"78","author":"Francini","year":"2018","journal-title":"Prostate"},{"key":"10.1016\/j.eururo.2025.01.010_b0025","doi-asserted-by":"crossref","unstructured":"Gillessen S, Turco F, Davis ID, et al. Management of patients with advanced prostate cancer. report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC). Eur Urol. In press. https:\/\/doi.org\/10.1016\/j.eururo.2024.09.017.","DOI":"10.1016\/j.eururo.2024.09.017"},{"key":"10.1016\/j.eururo.2025.01.010_b0030","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1470-2045(12)70560-0","article-title":"Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial","volume":"14","author":"Gravis","year":"2013","journal-title":"Lancet Oncol"},{"issue":"7_suppl","key":"10.1016\/j.eururo.2025.01.010_b0035","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1200\/jco.2015.33.7_suppl.140","article-title":"Androgen deprivation therapy (ADT) plus docetaxel (D) versus ADT alone for hormone-na\u00efve metastatic prostate cancer (PCa): Long-term analysis of the GETUG-AFU 15 phase III trial","volume":"33","author":"Gravis","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.01.010_b0040","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial","volume":"36","author":"Kyriakopoulos","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.01.010_b0045","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1093\/annonc\/mdz396","article-title":"Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial","volume":"30","author":"Clarke","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2025.01.010_b0050","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/S1470-2045(23)00230-9","article-title":"Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials","volume":"24","author":"Vale","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2025.01.010_b0055","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","article-title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial","volume":"20","author":"Fizazi","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2025.01.010_b0060","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2025.01.010_b0065","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.eururo.2019.08.006","article-title":"Abiraterone in \u201chigh-\u201d and \u201clow-risk\u201d metastatic hormone-sensitive prostate cancer","volume":"76","author":"Hoyle","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.01.010_b0070","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(23)00063-3","article-title":"Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial","volume":"24","author":"Sweeney","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2025.01.010_b0075","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1200\/JCO.22.00193","article-title":"Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer","volume":"40","author":"Armstrong","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.01.010_b0080","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/s41391-021-00436-y","article-title":"Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk","volume":"25","author":"Azad","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.eururo.2025.01.010_b0085","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1200\/JCO.20.03488","article-title":"Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study","volume":"39","author":"Chi","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.01.010_b0090","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/S1470-2045(19)30620-5","article-title":"Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study","volume":"20","author":"Agarwal","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2025.01.010_b0095","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1200\/JCO.21.00941","article-title":"Health-related quality of life in metastatic, hormone-sensitive prostate cancer: ENZAMET (ANZUP 1304), an international, randomized phase III trial led by ANZUP","volume":"40","author":"Stockler","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.01.010_b0100","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1002\/pros.24396","article-title":"The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroups","volume":"82","author":"Stenzl","year":"2022","journal-title":"Prostate"},{"key":"10.1016\/j.eururo.2025.01.010_b0105","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.1200\/JCO-24-01798","article-title":"Darolutamide in combination with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the phase III ARANOTE trial","volume":"42","author":"Saad","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.01.010_b0110","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200195","article-title":"Meta-analysis of candidate surrogate end points in advanced prostate cancer","volume":"2","author":"Gharzai","year":"2023","journal-title":"NEJM Evid"},{"key":"10.1016\/j.eururo.2025.01.010_b0115","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2\u2009\u00d7\u20092 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2025.01.010_b0120","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2025.01.010_b0125","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2025.01.010_b0130","doi-asserted-by":"crossref","first-page":"e1007","DOI":"10.1097\/01.JU.0001008804.84010.ec.18","article-title":"Darolutamide real-world doublet and triplet utilization in metastatic hormone sensitive prostate cancer (mHSPC): US community urology setting","volume":"211","author":"Lowentritt","year":"2024","journal-title":"J Urol"},{"issue":"6_suppl","key":"10.1016\/j.eururo.2025.01.010_b0135","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1200\/JCO.2023.41.6_suppl.41","article-title":"Geographic variation in utilization of doublet therapy for metastatic prostate cancer","volume":"41","author":"Washington","year":"2023","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.eururo.2025.01.010_b0140","doi-asserted-by":"crossref","first-page":"5065","DOI":"10.1200\/JCO.2022.40.16_suppl.5065","article-title":"Reasons for oncologist and urologist treatment choice in metastatic castration-sensitive prostate cancer (mCSPC): a physician survey linked to patient chart reviews in the United States","volume":"40","author":"Freedland","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.01.010_b0145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003998","article-title":"Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: long-term results from the STAMPEDE randomised controlled trial","volume":"19","author":"Parker","year":"2022","journal-title":"PLoS Med"},{"key":"10.1016\/j.eururo.2025.01.010_b0150","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.eururo.2018.09.008","volume":"75","author":"Boev\u00e9","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.01.010_b0155","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.eururo.2019.02.003","article-title":"Prostate radiotherapy for metastatic hormone-sensitive prostate cancer: a STOPCAP systematic review and meta-analysis","volume":"76","author":"Burdett","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.01.010_b0160","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/jama.280.11.969","article-title":"Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer","volume":"280","author":"D'Amico","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2025.01.010_b0165","unstructured":"National Comprehensive Cancer Network. NCCN guidelines version 4.2024. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf."},{"key":"10.1016\/j.eururo.2025.01.010_b0170","unstructured":"European Association of Urology. EAU - EANM - ESTRO - ESUR - ISUP - SIOG guidelines on prostate cancer. https:\/\/d56bochluxqnz.cloudfront.net\/documents\/full-guideline\/EAU-EANM-ESTRO-ESUR-ISUP-SIOG-Guidelines-on-Prostate-Cancer-2024_2024-04-09-132035_ypmy_2024-04-16-122605_lqpk.pdf."},{"key":"10.1016\/j.eururo.2025.01.010_b0175","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1002\/pros.24184","article-title":"Increasing rates of NCCN high and very high-risk prostate cancer versus number of prostate biopsy cores","volume":"81","author":"Wenzel","year":"2021","journal-title":"Prostate"},{"key":"10.1016\/j.eururo.2025.01.010_b0180","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.juro.2017.12.048","article-title":"Contemporary incidence and outcomes of prostate cancer lymph node metastases","volume":"199","author":"Bernstein","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.01.010_b0185","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/pros.24041","article-title":"Prostate cancer-specific mortality burden by risk group among men with localized disease: implications for research and clinical trial priorities","volume":"80","author":"Dee","year":"2020","journal-title":"Prostate"},{"key":"10.1016\/j.eururo.2025.01.010_b0190","unstructured":"EAU guidelines."},{"key":"10.1016\/j.eururo.2025.01.010_b0195","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.eururo.2024.07.026","article-title":"randomised trial of no, short-term, or long-term androgen deprivation therapy with postoperative radiotherapy after radical prostatectomy: results from the three-way comparison of RADICALS-HD (NCT00541047)","volume":"86","author":"Parker","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.01.010_b0200","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1200\/JCO.18.02158","article-title":"Effect of chemotherapy with docetaxel with androgen suppression and radiotherapy for localized high-risk prostate cancer: the randomized phase III NRG Oncology RTOG 0521 trial","volume":"37","author":"Rosenthal","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.01.010_b0205","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkac043","article-title":"Docetaxel for nonmetastatic prostate cancer: long-term survival outcomes in the STAMPEDE randomized controlled trial","volume":"6","author":"James","year":"2022","journal-title":"JNCI Cancer Spectr"},{"key":"10.1016\/j.eururo.2025.01.010_b0210","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0140-6736(21)02437-5","article-title":"Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol","volume":"399","author":"Attard","year":"2022","journal-title":"Lancet"},{"issue":"16_suppl","key":"10.1016\/j.eururo.2025.01.010_b0215","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS5103","volume":"40","author":"Niazi","year":"2022","journal-title":"J Clin Oncol"},{"issue":"4_suppl","key":"10.1016\/j.eururo.2025.01.010_b0220","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1200\/JCO.2024.42.4_suppl.328","article-title":"Baseline disease characteristics of participants enrolled on ENZARAD (ANZUP1303) and DASL-HiCaP (ANZUP1801) trials of highly effective androgen receptor antagonists in high-risk localized or locally advanced prostate cancer (PCa)","volume":"42","author":"Niazi","year":"2024","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.eururo.2025.01.010_b0225","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.TPS5087","article-title":"ATLAS: a randomized, double-blind, placebo-controlled, phase 3 trial of apalutamide (ARN-509) in patients with high-risk localized or locally advanced prostate cancer receiving primary radiation therapy","volume":"34","author":"Sandler","year":"2016","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.eururo.2025.01.010_b0230","doi-asserted-by":"crossref","first-page":"5084","DOI":"10.1200\/JCO.2022.40.16_suppl.5084","volume":"40","author":"Sandler","year":"2022","journal-title":"J Clin Oncol"},{"issue":"6_suppl","key":"10.1016\/j.eururo.2025.01.010_b0235","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.6_suppl.TPS156","article-title":"Randomised phase 3 trial of enzalutamide in androgen deprivation therapy (ADT) with radiation therapy for high risk, clinically localized prostate cancer: ENZARAD (ANZUP 1303)","volume":"36","author":"Williams","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.01.010_b0240","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","article-title":"Improved outcomes with enzalutamide in biochemically recurrent prostate cancer","volume":"389","author":"Freedland","year":"2023","journal-title":"N Engl J Med"},{"issue":"6_suppl","key":"10.1016\/j.eururo.2025.01.010_b0245","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.6_suppl.9","volume":"39","author":"Rathkopf","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.01.010_b0250","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2217\/fon-2023-0526","article-title":"TALAPRO-3 clinical trial protocol: phase III study of talazoparib plus enzalutamide in metastatic castration-sensitive prostate cancer","volume":"20","author":"Agarwal","year":"2024","journal-title":"Future Oncol"},{"issue":"16_suppl","key":"10.1016\/j.eururo.2025.01.010_b0255","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.8621","volume":"42","author":"Chi","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.01.010_b0260","doi-asserted-by":"crossref","first-page":"e628","DOI":"10.1016\/j.clon.2023.07.009","article-title":"The STAMPEDE2 trial: a site survey of current patterns of care, access to imaging and treatment of metastatic prostate cancer","volume":"35","author":"Abdel-Aty","year":"2023","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.eururo.2025.01.010_b0265","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","article-title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Agarwal","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2025.01.010_b0270","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200043","article-title":"Abiraterone and olaparib for metastatic castration-resistant prostate cancer","volume":"1","author":"Clarke","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.eururo.2025.01.010_b0275","unstructured":"Pfizer. Pfizer\u2019s TALZENNA\u00ae in Combination with XTANDI\u00ae prolongs overall survival in phase 3 TALAPRO-2 trial. Press release. October 10, 2024. https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizers-talzennar-combination-xtandir-prolongs-overall."},{"key":"10.1016\/j.eururo.2025.01.010_b0280","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S1470-2045(24)00440-6","article-title":"Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study","volume":"25","author":"Azad","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2025.01.010_b0285","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1038\/s41467-024-45475-w","article-title":"Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer","volume":"15","author":"Fonseca","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.eururo.2025.01.010_b0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102728","article-title":"Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer","volume":"54","author":"Kohli","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.eururo.2025.01.010_b0295","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1001\/jamaoncol.2021.3987","article-title":"Prognosis associated with luminal and basal subtypes of metastatic prostate cancer","volume":"7","author":"Aggarwal","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2025.01.010_b0300","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.euo.2024.04.011","article-title":"Prognostic and predictive role of SPOP mutations in prostate cancer: a systematic review and meta-analysis","volume":"7","author":"Pedrani","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2025.01.010_b0305","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.annonc.2021.06.003","article-title":"Transcriptional profiling of primary prostate tumor in metastatic hormone-sensitive prostate cancer and association with clinical outcomes: correlative analysis of the E3805 CHAARTED trial","volume":"32","author":"Hamid","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2025.01.010_b0310","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/s41391-021-00428-y","article-title":"Impact of Decipher biopsy testing on clinical outcomes in localized prostate cancer in a prospective statewide collaborative","volume":"25","author":"Vince","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.eururo.2025.01.010_b0315","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMoa041943","article-title":"Risk of fracture after androgen deprivation for prostate cancer","volume":"352","author":"Shahinian","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2025.01.010_b0320","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1002\/phar.2168","article-title":"Risks of major long-term side effects associated with androgen-deprivation therapy in men with prostate cancer","volume":"38","author":"Nguyen","year":"2018","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.eururo.2025.01.010_b0325","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.eururo.2019.11.021","volume":"77","author":"Matsubara","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.01.010_b0330","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.annonc.2023.02.009","article-title":"Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer","volume":"34","author":"Chowdhury","year":"2023","journal-title":"Ann Oncol"},{"issue":"6_suppl","key":"10.1016\/j.eururo.2025.01.010_b0335","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1200\/JCO.2022.40.6_suppl.123","article-title":"Survival outcomes and characterization of patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) undergoing intensified androgen deprivation therapy (ADT) who do not achieve an optimal PSA response (PSA \u22640.2 ng\/mL)","volume":"40","author":"Sayegh","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.01.010_b0340","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1111\/bju.16449","article-title":"Targeted Investigational Treatment Analysis of Novel Anti-androgen (TITAN) study: ultralow prostate-specific antigen decline with apalutamide plus androgen-deprivation therapy","volume":"134","author":"Merseburger","year":"2024","journal-title":"BJU Int"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283825000235?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283825000235?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T16:05:13Z","timestamp":1742313913000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283825000235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":68,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S0302283825000235"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2025.01.010","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination Therapies in Locally Advanced and Metastatic Hormone-sensitive Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2025.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}